Chlortetracycline


Full Generic Medicine Info
Dosage/Direction for Use

Ophthalmic
Ocular infections
Adult: As 1% ophthalmic ointment: Apply sparingly into the affected eye(s) 3-4 times daily. Dosage recommendations may vary among individual products or between countries (refer to detailed product guidelines).
Contraindications
Hypersensitivity.
Adverse Reactions
General disorders and administration site conditions: Local irritation at the site of application. Immune system disorders: Hypersensitivity reaction. Skin and subcutaneous tissue disorders: Photosensitivity, skin rash.
Action
Chlortetracycline is a tetracycline derivative that prevents protein synthesis by binding with the 30S and possibly 50S ribosomal subunit(s) of susceptible bacteria. It has a broad-spectrum antimicrobial activity against Gram-positive and Gram-negative organisms.
Storage
Ophthalmic: Store below 30°C. Protect from light.
CIMS Class
Eye Anti-Infectives & Antiseptics
ATC Classification
S01AA02 - chlortetracycline ; Belongs to the class of antibiotics. Used in the treatment of eye infections.
J01AA03 - chlortetracycline ; Belongs to the class of tetracyclines. Used in the systemic treatment of infections.
A01AB21 - chlortetracycline ; Belongs to the class of local antiinfective and antiseptic preparations. Used in the treatment of diseases of the mouth.
D06AA02 - chlortetracycline ; Belongs to the class of topical tetracycline and derivatives agents used in the treatment of dermatological diseases.
Disclaimer: This information is independently developed by CIMS based on chlortetracycline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in